Although HER2-positive early breast cancer patients in the community are less likely to complete a 12-month course of adjuvant trastuzumab than clinical trial counterparts, survival and recurrence rates in this real-world population are reassuringly comparable to those reported in landmark clinical trials. Here, ERBB2 is linked to breast cancer.